Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s): CRDL

Healthcare

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

TSX:CRDL - Post by User

Cardiol Therapeutics Inc > Phase 1 Acute Myocarditis Clinical Results?

<< Previous

Bullboard Posts

Next >>

Post by oracleofkingston Feb 16, 2021 9:49am

251 Views

Post# 32572128

Phase 1 Acute Myocarditis Clinical Results?

Has anyone heard anything regarding the timing of the release of the Phase 1 Pharmacokinetic study results? This is required before they launch in the Phase II Trial which is supposed to launch this quarter.

It would be also interested to hear last year's financial results, especially the Cortalex sales numbers.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading